Ubs Asset Management Americas Inc Coherus Bio Sciences, Inc. Transaction History

Ubs Asset Management Americas Inc

$381 Billion
Q3 2024

21 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 13, 2023	BUY	$3.74 - $5.45 $81,995 - $119,485	21,924 Added 19.25%	135,804 $507,000
Q1 2023 May 15, 2023	BUY	$5.89 - $10.52 $52,456 - $93,691	8,906 Added 8.48%	113,880 $778,000
Q4 2022 Feb 14, 2023	BUY	$5.69 - $10.07 $275,805 - $488,113	48,472 Added 85.79%	104,974 $831,000
Q3 2022 Nov 14, 2022	SELL	$7.17 - $13.87 $45,723 - $88,448	-6,377 Reduced 10.14%	56,502 $542,000
Q2 2022 Aug 12, 2022	SELL	$5.86 - $13.23 $93,947 - $212,103	-16,032 Reduced 20.32%	62,879 $455,000
Q2 2021 Aug 16, 2021	SELL	$12.95 - $15.41 $1.72 Million - $2.04 Million	-132,538 Reduced 62.68%	78,911 $1.09 Million
Q1 2021 May 14, 2021	SELL	$14.42 - $21.39 $29.5 Million - $43.7 Million	-2,042,457 Reduced 90.62%	211,449 $3.09 Million
Q4 2020 Mar 01, 2021	BUY	$16.56 - $18.94 $9.2 Million - $10.5 Million	555,584 Added 32.71%	2,253,906 $39.2 Million
Q3 2020 Nov 13, 2020	SELL	$17.41 - $19.89 $2.42 Million - $2.76 Million	-138,838 Reduced 7.56%	1,698,322 $31.1 Million
Q2 2020 Aug 14, 2020	SELL	$14.43 - $19.16 $317,705 - $421,845	-22,017 Reduced 1.18%	1,837,160 $32.8 Million
Q1 2020 May 15, 2020	SELL	$11.67 - $22.53 $680,325 - $1.31 Million	-58,297 Reduced 3.04%	1,859,177 $30.2 Million
Q4 2019 Feb 14, 2020	BUY	$16.33 - $21.37 $5.67 Million - $7.42 Million	346,993 Added 22.09%	1,917,474 $34.5 Million
Q3 2019 Nov 14, 2019	BUY	$16.3 - $23.37 $847,078 - $1.21 Million	51,968 Added 3.42%	1,570,481 $31.8 Million
Q2 2019 Aug 15, 2019	SELL	$13.1 - $22.1 $699,238 - $1.18 Million	-53,377 Reduced 3.4%	1,518,513 $0
Q1 2019 May 14, 2019	BUY	$8.38 - $15.5 $2.16 Million - $3.99 Million	257,191 Added 19.56%	1,571,890 $0
Q4 2018 Feb 13, 2019	BUY	$8.65 - $16.28 $457,256 - $860,593	52,862 Added 4.19%	1,314,699 $11.9 Million
Q3 2018 Nov 14, 2018	SELL	$14.45 - $20.25 $738,915 - $1.04 Million	-51,136 Reduced 3.89%	1,261,837 $0
Q2 2018 Aug 14, 2018	SELL	$10.25 - $17.45 $85,044 - $144,782	-8,297 Reduced 0.63%	1,312,973 $0
Q1 2018 May 14, 2018	SELL	$9.1 - $13.7 $658,758 - $991,756	-72,391 Reduced 5.19%	1,321,270 $0
Q4 2017 Feb 09, 2018	BUY	$8.35 - $14.4 $607,128 - $1.05 Million	72,710 Added 5.5%	1,393,661 $0
Q3 2017 Nov 13, 2017	BUY	$11.1 - $14.5 $14.7 Million - $19.2 Million	1,320,951	1,320,951 $0

Others Institutions Holding CHRS

# of Institutions

135

Shares Held

77.9M

Call Options Held

40.7K

Put Options Held

50.1K

Black Rock Inc. New York, NY

11.8M
Shares

$18.5 Million
0.0% of portfolio
Vanguard Group Inc Valley Forge, PA

11.3M
Shares

$17.8 Million
0.0% of portfolio
Rubric Capital Management LP New York, NY

10.4M
Shares

$16.3 Million
0.3% of portfolio
Kohlberg Kravis Roberts & Co. L.P. New York, NY

3.04M
Shares

$4.77 Million
0.18% of portfolio
Ken Griffin Citadel Advisors LLC | Chicago, Il

2.86M
Shares

$4.49 Million
0.0% of portfolio

View Full List

About Coherus BioSciences, Inc.

Ticker CHRS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 77,724,600
Market Cap $122M
Description
Coherus BioSciences, Inc., a biopharmaceutical company, focuses on the biosimilar and immuno-oncology market primarily in the United States. The company markets UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte stimulating colony factor in the United States. Its pipeline products include biosimilars of Humira, Avastin, and Lucentis. T...

More about CHRS

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Ubs Asset Management Americas Inc, based on Form 13F filings with the SEC.

News

Stay updated on Ubs Asset Management Americas Inc with notifications on news.

Account